Denileukin diftitox

Drug Profile

Denileukin diftitox

Alternative Names: DAB389IL-2; DAB389 interleukin-2; E7272; E7777; Interleukin-2 diphtheria toxin fusion protein; Interleukin-2 fusion toxin; LY 335348; ONTAK

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ajinomoto; Japanese Foundation for Cancer Research
  • Developer Eisai Co Ltd; TSD Japan
  • Class ADP ribose transferases; Antineoplastics; Bacterial toxins; Interleukins; Recombinant fusion proteins
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cutaneous T cell lymphoma
  • Phase II Malignant melanoma; Peripheral T-cell lymphoma
  • Discontinued Alopecia; Atopic dermatitis; HIV infections; Inflammatory bowel diseases; Multiple sclerosis; Psoriasis; Rheumatoid arthritis; Transplant rejection

Most Recent Events

  • 31 Mar 2016 Dr. Reddy's acquires the rights to develop and commercialise denileukin diftitox worldwide, excluding Asia and Japan
  • 15 Mar 2016 Biomarkers information updated
  • 01 Mar 2016 Phase-II clinical trials in Cutaneous T-cell lymphoma (Second-line therapy or greater) in Japan (IV) (NCT02676778)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top